A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib

Echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma kinase (EML4‐ALK) rearrangements are found in ~ 5% of patients with non‐small cell lung cancer (NSCLC). Several tyrosine kinase inhibitors (TKIs) have been developed for treatment of so‐called ALK‐positive NSCLC. In cases of tumor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Thorac Cancer
Glavni autori: Matsumura, Yuki, Inomata, Sho, Yamaguchi, Hikaru, Mine, Hayato, Takagi, Hironori, Watanabe, Masayuki, Ozaki, Yuki, Yamaura, Takumi, Fukuhara, Mitsuro, Muto, Satoshi, Okabe, Naoyuki, Hasegawa, Takeo, Shio, Yutaka, Suzuki, Hiroyuki
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons Australia, Ltd 2021
Teme:
Case Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8327688/
https://ncbi.nlm.nih.gov/pubmed/34159737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.14058
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items